At the Forefront

Social Workers’ Role in Psilocybin Treatment for Depression and Substance Misuse

Dados Bibliográficos

ID10554102
AutoresClaire Parker (0000-0002-7364-7046, School of Social Work, University of Texas at Arlington Claire Parker is a social work student, , 501 West Mitchell Street, Arlington, TX 76010, USA, autor correspondente), Bethany M Wood (0000-0003-1367-0508, The University of Texas at Arlington)
Ano2024
Volume69
Fascículo3
Páginas297-302
Data de publicação2024-05-02
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoSocial Work (JOURNAL)
Identificadores do periódicoISSN: 0037-8046 • E-ISSN: 1545-6846
EditoraOxford University Press (OUP) (PUBLISHER)
DOI10.1093/sw/swae019
PMID38697188
OpenAlexW4396599639
IdiomaEN
Citações recebidas1
Referências citadas31

This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating major depressive disorder (MDD) and substance use disorder (SUD). Contemporary treatments for MDD often have side effects, and the success rate for SUD treatments remains low. The pervasiveness of MDD, combined with the challenges in treating SUD, highlights a need for innovative treatments. This article provides an overview of the resurgence of literature over the past two decades that illuminates the therapeutic promise of psilocybin for mental health treatment; clinical trials elucidate the efficacy of psilocybin-assisted therapy in mitigating MDD and demonstrate great promise in reducing SUD symptoms. The long-lasting posttreatment effect emphasizes its potential as a novel treatment modality. Furthermore, psilocybin's recognition as a "breakthrough therapy" by the U.S. Food and Drug Administration (FDA) and the accelerating pace of psychedelic reform bills indicate growing acceptance and interest in its therapeutic capacities. Psilocybin-assisted therapy emerges as a potent treatment option, showcasing remarkable effectiveness even after a single dose. Recommendations and pathways for social workers to be involved in psilocybin-assisted therapy investigation, advocacy, and implementation are provided

Cognition · Hallucinogen · Major depressive disorder · Psilocybin · Psychiatry · Psychotherapist · Substance abuse · Chemical synthesis and alkaloids · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Psychology